The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia

PURPOSE: Acalabrutinib (ACP-196) is a novel, potent, and highly selective BTK inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the anti-tumor effects of acalabrutinib treatment in two established mouse models of chronic lymphocytic leukemia (CLL). E...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Herman, Sarah E. M., Montraveta, Arnau, Niemann, Carsten U., Mora-Jensen, Helena, Gulrajani, Michael, Krantz, Fanny, Mantel, Rose, Smith, Lisa L., McClanahan, Fabienne, Harrington, Bonnie K., Colomer, Dolors, Covey, Todd, Byrd, John C., Izumi, Raquel, Kaptein, Allard, Ulrich, Roger, Johnson, Amy J., Lannutti, Brian J., Wiestner, Adrian, Woyach, Jennifer A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548968/
https://ncbi.nlm.nih.gov/pubmed/27903679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0463
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak